Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX

BACKGROUND/AIMS: Although many studies have reported the promising effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC) to increase resectability, only a few studies have recommended the use of first-line chemotherapeutic agents as neoadjuvant treatment for BRPC. The cu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Gut Liver
Glavni autori: Choi, Yoo Jin, Byun, Yoonhyeong, Kang, Jae Seung, Kim, Hyeong Seok, Han, Youngmin, Kim, Hongbeom, Kwon, Wooil, Oh, Do-Youn, Paik, Woo Hyun, Lee, Sang Hyub, Ryu, Ji Kon, Kim, Yong-Tae, Lee, Kyungbun, Kim, Haeryoung, Chie, Eui Kyu, Jang, Jin-Young
Format: Artigo
Jezik:Inglês
Izdano: Editorial Office of Gut and Liver 2021
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8129663/
https://ncbi.nlm.nih.gov/pubmed/32839360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl20070
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items